GRAF FINCKENSTEIN FRIEDRICH 4

What Happened

• Graf Finckenstein, Chief Medical Officer of Iovance Biotherapeutics (IOVA), received an award of 58,750 restricted stock units (RSUs) on March 9, 2026. The Form 4 reports the acquisition as a derivative award (code A) with a $0.00 per-share price; no immediate cash value or sale was reported.

Key Details

• Transaction date: 2026-03-09; Form 4 filed: 2026-03-11 (filed timely).
• Security: 58,750 RSUs (each RSU represents a contingent right to one share).
• Reported price: $0.00 (typical for RSU grants); total grant value at issuance not stated on the Form 4.
• Shares owned after transaction: Not specified in the information provided on this filing.
• No 10b5-1 plan, tax-withholding sale, or immediate sale/exercise noted in the filing.

Context

• RSUs are a form of compensation/retention award that convert to actual shares only if and when they vest. Per the filing footnotes, these RSUs vest over three years: one-third on the one-year anniversary, then the remainder in eight equal quarterly installments over the following two years, and only if the reporting person remains employed.
• This is an award (compensation) rather than a market purchase or sale, so it signals company compensation practice rather than an immediate insider buy/sell decision.